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Important cost categories not
included: transcatheter aortic
valve implantation probably less
cost-effective
Patients eligible for the transcatheter aortic
valve implantation (TAVI) intervention are
old (>75 years), face a high risk of mortality,
and generally have multiple comorbidities.1
Healthcare consumption of this group of
patients can, therefore, be expected to be
high.2 3 As a consequence, life extension in
this group would probably result in addi-
tional healthcare consumption in so-called
life years gained. Healthcare consumption in
life years gained could be due to treatment of
a large variety of diseases related to old age
and/or consumption of long-term care due to
disabilities.
In the article by Watt et al,4 only a limited
set of cost categories is included, which
results in too favourable estimates of the
cost effectiveness of TAVI. Current NICE
guidelines do not advocate the inclusion of
medical costs in life years gained of diseases
not directly related to the intervention under
study.5 Ignoring costs that are relevant for
the NHS is difficult to defend using scientific
arguments.6e8 It also results in favouring
interventions that primarily increase length
of life over interventions that mainly
improve quality of life.9 Broadening the
perspective beyond the NHS, as Watts et al
suggest, would probably result in even less
favourable cost-effective estimates, as the
target group of TAVI does not participate in
the labour market anymore and, therefore,
consumes more than they produce.9 While
there may be uncomfortable implications of
including more cost categories that warrant
discussion, this can never be a reason to
exclude foreseeable costs.
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The Authors’ reply: Van Baal argues that
we have under-estimated the cost associated
with transcatheter aortic valve implantation
(TAVI) and as a result, we have generated
an overly-optimistic picture of its cost
effectiveness.1 This view is based on the
fact that we have not allowed for the cost
of managing the range of diseases (other
than aortic stenosis) that can be expe-
rienced during the additional years of life
that we estimate will result from the use of
TAVI rather than medical management. For
example, van Baal implies that we should
have included the cost associated with the
chance of lung cancer being diagnosed during
the additional years of life that have been
generated by TAVI. The authors are correct
in referring to arguments which have been
made in favour of the inclusion of these
‘unrelated’ costs in economic evaluation.
However, only a few of the health systems
around theworld,which use formal economic
evaluation to support decisions about the use
of new medical technologies, advocate the
inclusion of these costs. Given that our anal-
ysis adopted the perspective of the UK NHS
and the methodological guidelines published
by National Institute for Health and Clinical
Excellence,2 which do not support the
inclusion of ‘unrelated costs’, we did not
include these into our model. Furthermore, if
we had incorporated these costs, the inter-
pretation of the resulting cost effecti-
veness ratio would be unclear. This is
because the routine inclusion of such costs
would also need to be considered for all other
interventions provided by the National
Health Service which would then impact on
the cost effectiveness threshold against
which the TAVI cost effectiveness ratio is
compared.
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S McCusker, P McKavanagh, L Lusk, A
Agus, P Ball, M Harbinson, T Trinnick, E
Duly, G Walls, S Shevlin, C L McQuillan,
M Alkhalil, P Donnelly. BCS Abstracts
2012: 097 Calcium scores are more cost
effective for risk stratification than NICE’s
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